about
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome.Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis.The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.Diagnostic contribution of magnetic resonance imaging in an atypical presentation of motor neuron disease.Fingolimod reduces the clinical expression of active demyelinating lesions in MS.Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.Adiponectin profile at baseline is correlated to progression and severity of Multiple SclerosisClinical activity after fingolimod cessation: disease reactivation or rebound?Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare deliveryDeterminants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life studyOutcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort studyExtending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
P50
Q38649249-F9D20CBC-283B-49BF-B139-B7E51A550E33Q40446543-3962657E-F853-4E5C-AB21-F6230EB9891EQ41524426-FC431566-C267-4181-99FD-5B2B646966DAQ45722939-4406C8E4-76D9-4778-BCDF-82AB244D995FQ48748004-6F172C88-55F6-4F49-ABE2-A12845CAF3BDQ49677520-81B08139-A2C9-4C79-B114-9D1C8AE2E541Q50059511-C88FA44E-863C-4103-A18D-26908D5412C9Q53692680-D929B71F-B633-4F0F-AC8F-0225E20F2CF8Q57288586-36CFDD3F-B7C6-436A-A0BE-2132A9FB8302Q88932141-D041DDEA-B19D-4816-AB3B-E4F7FD8738A8Q90178590-2AC22144-6C90-4661-BB15-B7FCF6FD101CQ90463758-192748B4-934B-4897-87D3-22A136957F03Q92828116-9010A5AF-A089-4361-9168-0457048BCB21Q92885645-0017D94A-DFF4-47D9-93DD-5397ECFAC59C
P50
description
researcher
@en
wetenschapper
@nl
name
Elisabetta Signoriello
@en
Elisabetta Signoriello
@nl
type
label
Elisabetta Signoriello
@en
Elisabetta Signoriello
@nl
prefLabel
Elisabetta Signoriello
@en
Elisabetta Signoriello
@nl
P31
P496
0000-0001-5753-6752